Abstract |
Low expression of p27(Kip1) is associated with disease progression and an unfavorable outcome in several malignancies including oral squamous cell carcinoma (SCC). In addition, p27(Kip1) protein is thought to be degraded by Skp2 ( S-phase kinase-associated protein 2). The purpose of this study was to examine whether Skp2 expression can be a useful prognostic factor in oral SCC patients treated by UFT in combination with radiation. The Skp2 expression was investigated by immunohistochemistry in biopsy samples from 102 oral SCC patients, who were treated by UFT in combination with radiation. Associations of each expression with the clinicopathological characteristics and patient survival were also analyzed. A significant association was found between Skp2 expression and tumor size (p = 0.0462), cervical lymph node metastasis (p = 0.0209), therapeutic effect (p = 0.0490) and patient outcome (p = 0.0002). The 5-year survival rates of Skp2 high and low expression tumors were 40.5% and 78.5%, respectively, and this difference was significant (p = 0.0001) by log-rank test. Multivariate analysis revealed that reduced term of survival was related to high levels of Skp2 expression (p = 0.0001). These results suggest that Skp2 may be a useful prognostic factor in oral SCC patients treated by UFT in combination with radiation.
|
Authors | Koji Harada, Supriatno, Shin-Ichi Kawaguchi, Yuichiro Kawashima, Yasutaka Itashiki, Hideo Yoshida, Mitsunobu Sato |
Journal | Anticancer research
(Anticancer Res)
2005 May-Jun
Vol. 25
Issue 3c
Pg. 2471-5
ISSN: 0250-7005 [Print] Greece |
PMID | 16080478
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- S-Phase Kinase-Associated Proteins
- Tegafur
- Uracil
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, metabolism, radiotherapy, therapy)
- Combined Modality Therapy
- Female
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Mouth Neoplasms
(drug therapy, metabolism, radiotherapy, therapy)
- Prognosis
- S-Phase Kinase-Associated Proteins
(biosynthesis)
- Survival Rate
- Tegafur
(administration & dosage)
- Uracil
(administration & dosage)
|